Clinical Trials Logo

Filter by:
NCT ID: NCT05609968 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Start date: February 6, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).

NCT ID: NCT05609708 Recruiting - Genetic Disease Clinical Trials

Technological Development and Clinical Parallel Testing of PGT-G

Start date: December 12, 2022
Phase:
Study type: Observational

Preimplantation genetic testing (PGT) has three different testings according to the type of genetic disease, which was classified as PGT-M, PGT-SR and PGT-A. If the couple is tested for two different genetic diseases at the same time, it is necessary to customize the probe and adopt different detection methods, which increases the cost and cycle of testing. Advanced expert pre-experimental analysis is required for PGT-M in couples with monogenic disease. If the family members are unavailable, only the polar bodies, sperms or affected embryos can be used to analysis, which not only increases the risk of failure, but also increases the difficulty of detection. At present, BGI has developed a new single-tube complete Long fragment whole genome sequencing (stLFR-WGS) technology, which uses the same molecular tag on the short read sequencing fragments from the same long DNA molecule to achieve accurate short read sequencing to obtain long DNA information. Multiple genetic abnormalities such as gene variation, chromosome aneuploidy and chromosome structure rearrangement can be directly detected in embryos without pre-experiment of family members, so as to achieve universal normalization of the three PGT methods and solve the PGT detection needs of patients with multiple genetic diseases.

NCT ID: NCT05609630 Recruiting - Clinical trials for Juvenile Idiopathic Arthritis

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

SELECT-sJIA
Start date: October 2, 2023
Phase: Phase 3
Study type: Interventional

Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other types of juvenile idiopathic arthritis. It is a lifelong disease for many patients and can continue into adulthood. This study will assess how safe and effective upadacitinib is in treating pediatric and adolescent participants aged 1 to < 18 with systemic juvenile idiopathic arthritis (sJIA) and will include a tocilizumab treatment arm for reference. Adverse events and change in the disease activity will be assessed. Upadacitinib is an investigational drug being developed for the treatment of sJIA. Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive upadacitinib or tocilizumab reference. In cohort 2, participants will receive upadacitinib. Approximately 90 participants with sJIA will be enrolled in approximately 45 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily or tocilizumab subcutaneous injection or intravenous infusion as per local label for 52 weeks and followed for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits/calls during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

NCT ID: NCT05609591 Recruiting - Bowel Preparation Clinical Trials

Three Dietary Regimens in Pre-colonoscopic Bowel Preparation in Children

Start date: November 9, 2022
Phase: N/A
Study type: Interventional

To describe the feasibility and effectiveness of three dietary regimens in precolonoscopy bowel preparation in children

NCT ID: NCT05609370 Recruiting - Clinical trials for Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Start date: January 29, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine to participants with colorectal cancer.

NCT ID: NCT05609110 Recruiting - Clinical trials for Intracranial Hemorrhages

Safety and Efficacy of Remote Ischemic Conditioning for Spontaneous Intracerebral Hemorrhage

Start date: February 2, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning in treating acute intracerebral hemorrhage.

NCT ID: NCT05609058 Recruiting - Breast Cancer Clinical Trials

The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Radiotherapy after breast conserving therapy plays an important role in early stage breast cancer patients. It not only results in a reduction in local and regional recurrence but also decrease the death rate effectively. For adjuvant radiotherapy, supine positioning is the most common approach and has multiple advantages. Due to deformability and softness of the breast, during simulation and treatment in supine position, the breast stretches over the chest wall, especially in patients with large and pendulous glands. Thus the organs at risk (OARs) received dose increased. The radiotherapeutic toxicity are unavoidable. Some present studies show that the prone positioning of patients can improve dose homogeneity and reduce the dose distribution in OARs in patients with large and pendulous glands. Chinese women have relatively small breasts, the advantages of those have not been established. Therefore, investigators compared the parameters between supine and prone positions for whole breast irradiation after conserving surgery.

NCT ID: NCT05608980 Recruiting - Blepharitis Clinical Trials

0.01% Hypochlorous Acid in the Treatment of Blepharitis

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.

NCT ID: NCT05608759 Recruiting - Surgery Clinical Trials

Exercise Prehabilitation for Patients With NSCLC Before Surgery

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

To explore the safety and compliance of a wearable telemedicine device that can receive basic vital signs in real time, and its active supervision mode with real-time adjustment of exercise prescription for preoperative prehabilitation exercises in patients at home; and to evaluate the effectiveness of preoperative prehabilitation exercises in a telemedicine active supervision mode in patients undergoing thoracoscopic lung tumour resection, taking into account the patient's cardiopulmonary exercise test, postoperative complications and quality of life scores.

NCT ID: NCT05608512 Recruiting - Hospitalism Clinical Trials

Emotional Labor, Physical Labor and Mental Labor of Hospice Care Nurses: A Mixed-method Study

Start date: February 1, 2022
Phase:
Study type: Observational

Hospice care is a nurse-led multidisciplinary team care that provides physical, mental, and social care to end-of-life patients. According to the WHO, the role of hospice nurses is addressing suffering involves taking care of issues beyond physical symptoms, to support patients and their caregivers. Different from other disease care, hospice nurses face end-of-life patients and their families. As the primary nursing contact of a dying family, hospice nurses have a more intense and complex emotional experience. In China, with the improvement of human rights protection awareness, the nurse-patient relationship is particularly important, and the social requirements for nursing workers are also getting higher and higher. In addition, hospice nurses not only provide physical and psychological care to patients, but also provide comprehensive care to families of end-of-life patients. It is not just the mental work of learning expertise and dealing with emergency situations, and the physical labor of caring for large numbers of patients; but also requires emotional labor that has rarely been recognized before. When facing end-of-life patients and their families, it is particularly important to express appropriate emotions and pay emotional labor.